Join experts from Cleveland Clinic and around the world at a CME-certified official review in Hollywood, Florida.
Hit the highlights from the 2017 San Antonio Breast Cancer Symposium™ with a one-day official Best of SABCS review sponsored by Cleveland Clinic Florida and endorsed by the Florida Society of Clinical Oncology.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
SABCS is the premier conference in the U.S. and the world designed to provide the latest on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease to health professionals, physicians and researchers.
This review course is directed primarily towards academic physicians and researchers involved in breast cancer in medical, surgical, gynecologic and radiation oncology, as well as other appropriate health care professionals.
Topics include:
Zeina Nahleh, MD, FACP, Director of the Maroone Cancer Center and Chair of the Department of Hematology/Oncology at Cleveland Clinic Florida, will lead the course.
Faculty include Cleveland Clinic experts Jame Abraham, MD, George Thomas Budd, MD, and Margaret Thompson, MD, as well as guest faculty Helen Chew, MD, of University of California Davis Cancer Center and Debu Tripathy, MD, of University of Texas MD Anderson Cancer Center.
This course will enable you to report the most current information on breast cancer research presented at SABCS in December, discuss the information with colleagues and key opinion leaders, and integrate into clinical practice various evidence-based advances to management in imaging, surgery and local and systemic therapies surrounding HER2+, BRCA-related breast cancer, hormonal therapy, molecular predictions models and survivorship.
For a full agenda and to register, visit the program site.
This activity has been approved for AMA PRA Category 1 credit™.
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust